Video

Pharmacist Medication Insights: Hizentra for Primary Immunodeficiency

Author(s):

Saro Arakelians, PharmD

Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.

Hizentra is an immune globulin subcutaneous (Human) (IGSC), 20%. It is indicated for the treatment of primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Related Content
Infusion management: Close-up of a butterfly cannula
June 6th 2025

SCIg More Effective Immunoglobulin Option for Immunocompromised Patients With Inborn Errors of Immunity

Luke Halpern, Assistant Editor
When Placebo Plus Standard of Care Clouds the Signal: Unmasking the “Placebo Problem” in Lupus Clinical Trials
June 6th 2025

When Placebo Plus Standard of Care Clouds the Signal: Unmasking the “Placebo Problem” in Lupus Clinical Trials

Juan Ovalles, MD, PhD Alana Hippensteele, Lead Editor
Injectors and dosing pens for subcutaneous injection of antidiabetic medications or a anti-obesity medication lying on a pink backdrop, top view. Medicine and weight loss, concept.
June 4th 2025

Recombinant Human Hyaluronidase-Facilitated SCIg Sustains Clinical Remission in Idiopathic Inflammatory Myositis

Luke Halpern, Assistant Editor
Microscopic View of Hematological Slide Showing Thrombocytopenia and Low Platelet Count in Blood
May 31st 2025

IVIG Increases Platelet Counts in Pregnant Patients With Severe Thrombocytopenia, With Identifiable Aspects of Response

Luke Halpern, Assistant Editor
A little asian girl is sick in the hospital,Kawasaki disease
May 22nd 2025

Additional Dose of IVIG Provides Positive Therapeutic Effect in Patients With Infliximab-Refractory Kawasaki Disease

Luke Halpern, Assistant Editor
Doctor hold Blood sample for Primary Immunodeficiency (PID) test. Medical testing concept with laboratory background.
May 13th 2025

Mild to Moderate Adverse Events Possible in Pediatric Patients With Primary Immunodeficiency Receiving IVIG

Luke Halpern, Assistant Editor